Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginNet MarginOperating MarginReturn on Sales

ProQR Therapeutics (PRQR) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to 382.69%.

  • ProQR Therapeutics' EBITDA Margin rose 1618900.0% to 382.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 162.34%, marking a year-over-year increase of 927000.0%. This contributed to the annual value of 146.58% for FY2024, which is 3039300.0% up from last year.
  • Latest data reveals that ProQR Therapeutics reported EBITDA Margin of 382.69% as of Q3 2025, which was up 1618900.0% from 336.94% recorded in Q2 2025.
  • ProQR Therapeutics' 5-year EBITDA Margin high stood at 8668.09% for Q1 2021, and its period low was 7565.69% during Q4 2021.
  • In the last 5 years, ProQR Therapeutics' EBITDA Margin had a median value of 231.25% in 2025 and averaged 756.51%.
  • Within the past 5 years, the most significant YoY rise in ProQR Therapeutics' EBITDA Margin was 59390200bps (2022), while the steepest drop was -74384400bps (2022).
  • Over the past 5 years, ProQR Therapeutics' EBITDA Margin (Quarter) stood at 7565.69% in 2021, then skyrocketed by 78bps to 1626.67% in 2022, then skyrocketed by 88bps to 190.86% in 2023, then decreased by -23bps to 234.06% in 2024, then skyrocketed by 263bps to 382.69% in 2025.
  • Its EBITDA Margin was 382.69% in Q3 2025, compared to 336.94% in Q2 2025 and 231.25% in Q1 2025.